364 related articles for article (PubMed ID: 23720093)
1. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
2. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
Smith BD; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Shirvani SM
J Geriatr Oncol; 2015 Jul; 6(4):324-31. PubMed ID: 26094172
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research.
Grutters JP; Pijls-Johannesma M; Ruysscher DD; Peeters A; Reimoser S; Severens JL; Lambin P; Joore MA
Cancer Treat Rev; 2010 Oct; 36(6):468-76. PubMed ID: 20303217
[TBL] [Abstract][Full Text] [Related]
10. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis.
Ferguson MK
J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1935-42. PubMed ID: 14688709
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases.
Lester-Coll NH; Rutter CE; Bledsoe TJ; Goldberg SB; Decker RH; Yu JB
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):663-72. PubMed ID: 27055395
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
[TBL] [Abstract][Full Text] [Related]
16. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
[TBL] [Abstract][Full Text] [Related]
17. Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis.
Louie AV; Rodrigues G; Hannouf M; Lagerwaard F; Palma D; Zaric GS; Haasbeek C; Senan S
Radiother Oncol; 2011 May; 99(2):161-5. PubMed ID: 21620503
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
Lanni TB; Grills IS; Kestin LL; Robertson JM
Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
[TBL] [Abstract][Full Text] [Related]
20. Cost and effectiveness of radiofrequency ablation versus limited surgical resection for stage I non-small-cell lung cancer in elderly patients: is less more?
Alexander ES; Machan JT; Ng T; Breen LD; DiPetrillo TA; Dupuy DE
J Vasc Interv Radiol; 2013 Apr; 24(4):476-82. PubMed ID: 23462066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]